Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) were up 4.1% on Thursday . The stock traded as high as $4.15 and last traded at $4.09. Approximately 420,001 shares traded hands during trading, a decline of 75% from the average daily volume of 1,664,426 shares. The stock had previously closed at $3.93.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on AUTL. Needham & Company LLC reiterated a "buy" rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research note on Friday, April 12th. Truist Financial boosted their price target on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Autolus Therapeutics has an average rating of "Moderate Buy" and an average target price of $8.70.
Check Out Our Latest Report on AUTL
Autolus Therapeutics Trading Up 3.6 %
The stock's 50 day moving average price is $5.04 and its two-hundred day moving average price is $5.31. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -3.42 and a beta of 2.03.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.18). On average, sell-side analysts forecast that Autolus Therapeutics plc will post -0.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Autolus Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of AUTL. Bayesian Capital Management LP acquired a new position in shares of Autolus Therapeutics in the first quarter valued at approximately $100,000. China Universal Asset Management Co. Ltd. acquired a new position in Autolus Therapeutics in the 4th quarter valued at $105,000. B. Riley Wealth Advisors Inc. acquired a new position in Autolus Therapeutics in the 1st quarter valued at $108,000. SG Americas Securities LLC purchased a new position in shares of Autolus Therapeutics during the 1st quarter worth $127,000. Finally, EntryPoint Capital LLC boosted its holdings in shares of Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company's stock worth $137,000 after purchasing an additional 11,456 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.
Autolus Therapeutics Company Profile
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Articles
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
